欣维宁在急诊经皮冠状动脉介入治疗急性心肌梗死中的应用探讨  

Effect of tirofiban in STEMI patients undergoing emergency percutaneous coronary intervention

作　　者：苏振琪 袁争百 韩宏华[1] 陈大顺 

机构地区：[1]安徽淮北矿工总医院集团心内科,安徽235000

出　　处：《当代医学》2010年第5期97-98,共2页Contemporary Medicine

摘　　要：目的研究国产替罗非班(欣维宁)对急性心肌梗死病人行急诊经皮冠状动脉介入治疗的疗效及安全性。方法入选2004～2008年急性心肌梗死病人41例并同意行急诊PCI术,其中20例为对照组:常规术前口服阿斯匹林300mg、氯吡格雷300mg,术中、术后使用肝素。21例为欣维宁组:除常规用药同对照组外,术前、术中及术后使用欣维宁(国产替罗非班),分析罪犯血管(IRA)再通情况、出血及急性、亚急性血栓事件和对血小板的影响。结果欣维宁组手术成功率99.8%,IRATIMI3级占90.48%出血率23.9%,为渗血、小血肿,无严重后果。未发生急性、亚急性血栓事件。对照组:手术成功率90%,IRA开通后TIMI3级血流占75%,出血率5%,急性、亚急性血栓形成占据15%。讨论急性心肌梗死病人行急诊经皮冠脉介入治疗术中使用欣维宁是安全有效的,提高IRA再通率,缺血、损伤心肌灌注改善显著。Objective To investigate the clinical outcomes and safety of tirofiban in STEMI patiens undergoing emergency percutaneous coronary intervention（PCI）.Methods A total of 41 patients who underwent primary PCI.between January 2004 to January 2008 were divided two groups;the tirfiban treatment group（n=21）and the control group（n=20）.TIMI grade,the rate of bleeding,transfusion,the count of thrombocyte,thrombosis were compared.Results There was difference between the two groups in percentage of TIMI3 flow achieved in IRA,thrombosis,the rate of bleeding after PCI（P0.05）.There was no difference between the two groups in the count of thrombocyte.Conclusisons Application of tirofiban during primary PCI in patients with AMI is safe and effective which improves microvascular.

关 键 词：替罗非班 急性心肌梗死 急诊经皮冠脉介入治疗 

分 类 号：R542.22[医药卫生—心血管疾病]